What Is Kream Next Gen? Ingredients, Formats & What to Know
Kream Next Gen is one of the more structurally unusual products on the current botanical shelf. Where most cat's-claw brands build around a single plant, Kream publishes a three-botanical formula: Uncaria tomentosa, Picralima nitida, and Kanna. The brand states plainly that the product is not kratom and is not made with Mitragyna speciosa.
This guide covers what Kream publishes about the line — per-tablet strength, pack configuration, the ingredient split, flavors, and its testing claims — along with background on the three plants involved, since two of them are less familiar than cat's claw. Everything here comes from published retail specifications. Where a figure could not be verified, it is omitted rather than estimated. We sell cat's claw products ourselves; nothing below is a knock on Kream, which is an operating brand in a legal retail category.
What Kream Next Gen Sells
The product is a chewable pressed tablet, listed at retail as Kream Next Gen Botanical Tablets. The core published specification is consistent across sellers: 200mg per tablet, four tablets per pack, 800mg total.
The 200mg figure is a per-tablet number, and the 800mg figure that appears in some listings and wholesale titles is the pack total. Both are published; they measure different things. Kream's own serving guidance describes one quarter of a tablet as a serving, which works out to sixteen servings per four-tablet pack.
That quarter-tablet framing is worth registering, because it means the headline number, the tablet, and the suggested serving are three separate quantities. A pack advertised as 800mg is described by the brand as sixteen servings.
The Three Botanicals
The multi-plant structure is Kream's actual point of differentiation, so it is worth knowing what each component is.
Uncaria tomentosa (cat's claw)
A woody climbing vine native to the Amazon basin, named for the hooked thorn-like structures at its leaf nodes. It naturally contains indole and oxindole alkaloids and polyphenols. It has a long record of traditional use among Indigenous Amazonian communities — historical and cultural context only, not evidence of any effect. Several unrelated plants share the "cat's claw" common name, which is why the Latin binomial matters. Our primer is at what is cat's claw.
Picralima nitida
A tree native to West and Central Africa, commonly called akuamma. Its seeds are the part traditionally used, and they contain their own set of indole alkaloids. Like cat's claw, it is botanically unrelated to Mitragyna speciosa — though both Picralima and Mitragyna sit within the broad Apocynaceae-and-Rubiaceae grouping of alkaloid-bearing plants, which is a very wide net. It has traditional use in West African herbal practice, again as historical context only.
Kanna
Sceletium tortuosum, a succulent native to South Africa, where it has a long documented history of traditional use among Khoisan peoples. It is not an alkaloid-bearing plant of the same class as the other two — it belongs to a different family entirely, and its constituent profile is distinct. Kanna appears in a range of consumer botanical products in the US market. Its inclusion here is what makes the formula genuinely three-plant rather than two related species plus a flavoring.
Published Specifications
| Specification | Published figure |
|---|---|
| Product type | Chewable pressed tablet |
| Per-tablet strength | 200mg botanical blend |
| Tablets per pack | 4 |
| Total per pack | 800mg |
| Serving guidance | 1/4 tablet; 16 servings per pack |
| Botanicals | Uncaria tomentosa, Picralima nitida, Kanna |
| Blend split | Listings describe an even three-way split of the 200mg (roughly 66.67mg each) |
| Flavors | Grape, Pineapple |
| Other ingredients | Microcrystalline cellulose, dicalcium phosphate, silicon dioxide, magnesium stearate, natural flavoring |
| Kratom content | Stated as not kratom; not made with Mitragyna speciosa |
| Testing | Third-party testing referenced as reporting non-detectable mitragynine and 7-hydroxymitragynine |
| Retail pricing | Varies by retailer |
Some distributor listings reference a bulk configuration at a higher aggregate milligram figure; that reflects multiple retail packs in a display carton rather than a different tablet. We were not able to verify extract standardization ratios for any of the three botanicals, a manufacturing location, or which plant part each extract is drawn from, so none of those are stated here.
On the even three-way split
Kream's listings present the 200mg as divided roughly equally among the three botanicals — about 66.67mg apiece. That is a more informative disclosure than a flat proprietary blend figure, because it tells you how the total is apportioned rather than leaving the internal composition undisclosed.
Two caveats keep it in perspective. First, an equal split by mass is a formulation choice, not a statement that the three contribute equally to anything. Second, extract mass is a weight, not a concentration. Without a published standardization ratio, 66.67mg of one extract and 66.67mg of another are equal only in how much material is present.
Testing and the "Not Kratom" Statement
Kream is more specific than most brands in this category about how it substantiates its kratom-free positioning. Rather than only asserting that the product is not kratom, its listings reference third-party testing reporting non-detectable levels of mitragynine and 7-hydroxymitragynine in the tested formulation.
That is the right shape of claim, and it is worth understanding why. "Non-detectable" is a result relative to a method's limit of detection — it means the analysis did not find the compound above the threshold the method could resolve. A meaningful non-detect result is therefore tied to a specific test method, a specific limit, and a specific batch. When you evaluate a brand's testing claim, the useful questions are: which lab, which batch, what compounds were on the panel, and what were the detection limits.
None of this is unique to Kream — it is the standard any brand's documentation should meet, ours included. Our batch documentation is at our COA page.
Why Kratom-Free Positioning Is Everywhere Right Now
The reason nearly every brand in this category leads with a kratom-free statement is a specific, dated federal action.
On July 1, 2026, the Drug Enforcement Administration filed Notices of Intent to temporarily place 7-hydroxymitragynine above a threshold into Schedule I of the Controlled Substances Act, alongside mitragynine pseudoindoxyl, MGM-15, and MGM-16. The notices published in the Federal Register on July 6, 2026. The temporary scheduling order publishes on or after August 5, 2026, is effective on publication, and lasts two years while the agency can pursue permanent scheduling. Thresholds are 0.05% for leaf material and 0.05% or 1mg per article for extracts, concentrates, and pressed pills. The announcement is at dea.gov.
The compounds named are associated with Mitragyna speciosa. None of the three plants in Kream's formula is that species, and none naturally contains those alkaloids. A brand stating that its product is not kratom is describing its ingredient panel, not claiming an exemption. The federal action applies by substance, concentration, and quantity rather than by brand name or marketing category. Our plain-language walkthrough is at is 7-OH banned.
State law is a separate layer that varies by jurisdiction and by formulation. Nothing here is legal advice, and questions about a specific state are for a qualified attorney.
How the Multi-Botanical Approach Compares
Most cat's-claw brands ship a physically similar product — a flavored chewable tablet in a small count — and differentiate on what the label says is inside.
Kream sits at the multi-plant end. Single-botanical brands publish one extract weight and are the easiest to reason about. Proprietary-blend brands publish a total without itemizing components. Complex-formula brands bundle the botanical with vitamins or other compounds under a branded name. Kream's approach names three plants and states how the total divides among them, which is more disclosure than a proprietary blend and more complexity than a single-ingredient tablet.
More ingredients also means more variables. Each additional botanical is another supply chain, another extraction process, and another set of constituents that testing has to account for. That is not a criticism — it is simply what a shopper is taking on when choosing a multi-plant formula over a single-plant one, and it raises the value of batch-level documentation accordingly.
If you want the broader category view first, our overview of the base botanical is at what is cat's claw, and our own single-botanical products are in the cat's claw collection.
Frequently Asked Questions
What is in Kream Next Gen?
Published listings name three botanicals — Uncaria tomentosa (cat's claw), Picralima nitida, and Kanna — described as an even split of the 200mg per tablet, roughly 66.67mg each. Other ingredients listed are microcrystalline cellulose, dicalcium phosphate, silicon dioxide, magnesium stearate, and natural flavoring.
Is Kream Next Gen kratom?
No. The brand states the product is not kratom and is not made with Mitragyna speciosa, and its listings reference third-party testing reporting non-detectable mitragynine and 7-hydroxymitragynine. The three named botanicals are different plants that do not naturally contain those alkaloids.
How many milligrams is a Kream tablet?
200mg per tablet. A four-tablet pack totals 800mg, which is the figure that appears in some product titles. The brand's stated serving is one quarter of a tablet, giving sixteen servings per pack.
What is Picralima nitida?
A tree native to West and Central Africa, commonly called akuamma. Its seeds contain indole alkaloids and have a history of traditional use in West African herbal practice — historical context only, not evidence of effect. It is a distinct species from both cat's claw and kratom.
What flavors does Kream Next Gen come in?
Grape and Pineapple appear across retail listings. Availability rotates by retailer, so both are not always stocked in the same place at the same time.
These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Consult a qualified healthcare professional before use.